NCT04758260

Brief Summary

Evaluate the influence of antioxidant men supplements treatment (Fertybiotic Hombre) in the rate of sORP (stactic Oxidation Reduction Potential) defined as the balanced measure between the total oxidant activity (ROS, superoxides, nitric oxide, peroxide) and total reducing activity (alpha tocopherol, β carotene, uric acid) in sperm samples during egg donation cycles. We will also evaluate the influence of the sORP rate in the embryo development during the egg donation treatments; taking in account the fecundation rate, percentage of blastocyst stage arrival embryos, number of frozen embryos, implantation rate, on-going pregnancy rate and miscarriage rate. The sperm sample will be measured by electrochemical technology using Mioxsys system for a quantitative measurement in millivolts (mV), in those male patients who participate in an egg donation assisted reproduction treatment. After 14 days, the pregnancy stage will be available. This information will be obtained from the patient's clinical history using the human chorionic gonadotropin hormone (shCG) in blood. It will be performed either in our Clinic or externally within the usual practice derived from the treatment carried out. These values will be compared with the results obtained from sORP.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 12, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 18, 2019

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2020

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 12, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 17, 2021

Completed
Last Updated

February 17, 2021

Status Verified

February 1, 2021

Enrollment Period

5 months

First QC Date

March 9, 2020

Last Update Submit

February 12, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Compare the sORP rate in sperm samples,

    Compare the sORP rate in sperm samples, obtained by the Mioxsys System, before and after 2.5 months antioxidant men supplements treatment (Fertybiotic MAN).

    2.5 months

Secondary Outcomes (3)

  • Evaluate the influence of the sORP rate in embryo development

    1 year

  • Evaluate the relationship between the sORP rate in sperm samples

    1 year

  • Determinate a reproductive prognosis value based on sORP rate and the different sperm parameters

    1 year

Study Arms (1)

Antioxidant Treatment

EXPERIMENTAL

Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men

Dietary Supplement: Antioxidant

Interventions

AntioxidantDIETARY_SUPPLEMENT

Oral antioxidant oral intake in the 3 months prior to inclusion in the study

Antioxidant Treatment

Eligibility Criteria

Age18 Years - 48 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Sperm count greater than 2 million per milliliter
  • Sperm origin: ejaculate

You may not qualify if:

  • Total astenozoospermia or Severe teratozoospermia (including balloonzoospermia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IVI Bilbao

Leioa, Vizcaya, 48940, Spain

Location

MeSH Terms

Interventions

Antioxidants

Intervention Hierarchy (Ancestors)

Biological FactorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesProtective AgentsPhysiological Effects of DrugsSpecialty Uses of Chemicals

Study Officials

  • Marcos Ferrando

    IVI Bilbao

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Marcos Ferrando Serrano

Study Record Dates

First Submitted

March 9, 2020

First Posted

February 17, 2021

Study Start

February 12, 2019

Primary Completion

July 18, 2019

Study Completion

February 12, 2021

Last Updated

February 17, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations